Foster GR, et al. - Researchers undertook the C-ISLE study to assess the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) plus sofosbuvir (SOF) with and without ribavirin (RBV) in compensated cirrhotic participants with genotype (GT)3 infection. Treatment-naive participants were administered EBR/GZR+SOF+RBV for 8 weeks or EBR/GZR+SOF for 12 weeks. EBR/GZR+SOF±RBV for 12 weeks or EBR/GZR+SOF for 16 weeks was administered to peginterferon/RBV treatment-experienced participants. Outcomes supported the utility of EBR/GZR plus SOF for 12 weeks without RBV for treatment-naive and peginterferon/RBV–experienced people with GT3 infection and cirrhosis